Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048581
Status:
COMPLETED
Last Update Posted:
2011-11-21
First Post:
2002-11-02
Brief Title:
Phase III Study of BMS-188667 CTLA4Ig in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase III Multi-Center Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs DMARDS Who Have Failed Anti-Tumor Necrosis Factor TNF Therapy
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs DMARDs will relieve the symptoms of rheumatoid arthritis RA in participants who are currently receiving anti-tumor necrosis factor TNF therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond The safety of treatment with abatacept will also be evaluated This study also has a 45-year long-term extension beginning 6 months after the start of the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None